Amgen has announced positive results from Phase 3 trials of rocatinlimab for eczema and another antibody drug for myasthenia gravis. The rocatinlimab trial, dubbed Horizon, demonstrated significant efficacy in reducing eczema symptoms, while the myasthenia gravis treatment also showed success in the Mint trial.
Rocatinlimab Efficacy in Eczema
The Phase 3 Horizon trial evaluated rocatinlimab in patients with moderate to severe eczema. The results indicated that 32.8% of patients treated with rocatinlimab achieved at least a 75% improvement in the extent and severity of skin lesions (EASI-75) after 24 weeks, compared to 13.7% of those receiving a placebo. This statistically significant difference highlights the potential of rocatinlimab as a novel treatment option for eczema patients.
Reduction in Disease Severity
In addition to the EASI-75 endpoint, rocatinlimab also demonstrated superiority over placebo in reducing overall disease severity. This was measured by two different doctors’ assessments: the validated investigator global assessment and the revised investigator global assessment. These findings further support the clinical benefit of rocatinlimab in managing eczema symptoms and improving patients' overall condition.
Safety and Tolerability
Amgen reported that rocatinlimab was generally safe and well-tolerated in the Horizon trial. Detailed safety data will be crucial for regulatory review and understanding the overall risk-benefit profile of the drug.
Myasthenia Gravis Treatment Success
Amgen's other antibody drug targeting myasthenia gravis also succeeded in a late-stage trial. While specific details were not provided, the company noted that the treatment faces competition from existing therapies in the market.
